📣 VC round data is live. Check it out!
- Public Comps
- Zentalis Pharma
Zentalis Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Zentalis Pharma and similar public comparables like Santhera Pharma, IMBiologics, Prelude Therapeutics, Oryzon Genomics and more.
Zentalis Pharma Overview
About Zentalis Pharma
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
Founded
2014
HQ

Employees
166
Website
Financials (LTM)
EV
$104M
Valuation Multiples
Start free trialZentalis Pharma Financials
Zentalis Pharma reported last 12-month revenue of - and negative EBITDA of ($159M).
In the same LTM period, Zentalis Pharma generated - in gross profit, ($159M) in EBITDA losses, and had net loss of ($143M).
Revenue (LTM)
Zentalis Pharma P&L
In the most recent fiscal year, Zentalis Pharma reported revenue of - and EBITDA of ($144M).
Zentalis Pharma is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.
Financial data powered by Morningstar, Inc.
Zentalis Pharma Stock Performance
Zentalis Pharma has current market cap of $281M, and enterprise value of $104M.
Market Cap Evolution
Zentalis Pharma's stock price is $3.95.
Zentalis Pharma share price decreased by 1.3% in the last 30 days, and increased by 241.4% in the last year.
Zentalis Pharma has an EPS (earnings per share) of $-1.93.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $104M | $281M | -0.9% | -1.3% | 68.8% | 241.4% | $-1.93 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialZentalis Pharma Valuation Multiples
Zentalis Pharma trades at (0.7x) EV/EBITDA.
EV / Revenue (LTM)
Zentalis Pharma Financial Valuation Multiples
As of June 4, 2026, Zentalis Pharma has market cap of $281M and EV of $104M.
Zentalis Pharma has a P/E ratio of (2.0x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Zentalis Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Zentalis Pharma Margins & Growth Rates
Zentalis Pharma grew EBITDA by 18% in the last fiscal year.
Zentalis Pharma Margins
Zentalis Pharma Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Zentalis Pharma Operational KPIs
Zentalis Pharma's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.9M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Zentalis Pharma Competitors
Zentalis Pharma competitors include Santhera Pharma, IMBiologics, Prelude Therapeutics, Oryzon Genomics, Immuneering, Panacea Biotec, Organogenesis, Eledon Pharmaceuticals, Armata Pharmaceuticals and Egetis Therapeutics.
Most Zentalis Pharma public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 3.2x | 2.9x | (7.8x) | (11.9x) | |||
| - | 27.6x | - | - | |||
| 17.8x | 11.3x | (2.1x) | (2.0x) | |||
| - | 78.6x | (44.4x) | (25.5x) | |||
| - | - | (2.1x) | - | |||
| 3.9x | - | 79.5x | - | |||
| 0.7x | 0.9x | 4.1x | 17.7x | |||
| - | - | (2.0x) | - | |||
This data is available for Pro users. Sign up to see all Zentalis Pharma competitors and their valuation data. Start Free Trial | ||||||
Zentalis Pharma VC Funding History
Before going public, Zentalis Pharma raised $263M in total equity funding, across 3 rounds.
Zentalis Pharma Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Zentalis Pharma
| When was Zentalis Pharma founded? | Zentalis Pharma was founded in 2014. |
| Where is Zentalis Pharma headquartered? | Zentalis Pharma is headquartered in United States. |
| How many employees does Zentalis Pharma have? | As of today, Zentalis Pharma has over 166 employees. |
| Who is the CEO of Zentalis Pharma? | Zentalis Pharma's CEO is Julie M. Eastland. |
| Is Zentalis Pharma publicly listed? | Yes, Zentalis Pharma is a public company listed on Nasdaq. |
| What is the stock symbol of Zentalis Pharma? | Zentalis Pharma trades under ZNTL ticker. |
| When did Zentalis Pharma go public? | Zentalis Pharma went public in 2020. |
| Who are competitors of Zentalis Pharma? | Zentalis Pharma main competitors include Santhera Pharma, IMBiologics, Prelude Therapeutics, Oryzon Genomics, Immuneering, Panacea Biotec, Organogenesis, Eledon Pharmaceuticals, Armata Pharmaceuticals, Egetis Therapeutics. |
| What is the current market cap of Zentalis Pharma? | Zentalis Pharma's current market cap is $281M. |
| Is Zentalis Pharma profitable? | No, Zentalis Pharma is not profitable. |
| What is the current EBITDA of Zentalis Pharma? | Zentalis Pharma has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Zentalis Pharma? | Current EBITDA multiple of Zentalis Pharma is (0.7x). |
| How many companies Zentalis Pharma has acquired to date? | Zentalis Pharma hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Zentalis Pharma has invested to date? | Zentalis Pharma hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Zentalis Pharma
Lists including Zentalis Pharma
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.